Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Repligen Corporation(RGEN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RGEN
11/05/2026: RGEN (2-star) is currently NOT-A-BUY. Pass it for now.
Repligen Corporation is a specialized life sciences company providing essential, high-quality components for biopharmaceutical manufacturing. It is recognized for its high-margin consumable products, such as chromatography resins and filtration membranes, which are often specified early in drug development. Its primary investment story centers on the secular growth of biologic drugs, including cell and gene therapies. However, the company faces risks from industry-wide inventory cycles, intense competition from diversified life science giants, and valuation sensitivity. While Repligen has a leading position in its niches, it is a volatile growth stock suited for investors comfortable with sector-specific cycles rather than those seeking dividends or low-risk stability.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Repligen serves the high-growth bioprocessing market which benefits from the secular increase in biologic drug development. |
| Momentum investor | Mixed fit | The stock often tracks industry-wide bioprocessing sentiment and requires a positive sector upturn signal to confirm momentum. |
| Value investor | Weak fit | The stock frequently trades at a premium valuation due to its high-quality growth characteristics and specialized niche status. |
| Dividend investor | Weak fit | Repligen does not pay a dividend and focuses on reinvesting cash for growth. |
| Low-risk investor | Weak fit | The stock exhibits high volatility characteristic of small-to-mid-cap growth stocks in the biotechnology tools sector. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to sharp swings based on industry inventory cycles and biopharma capital spending. |
| Valuation risk | Medium / high | Investors often pay a premium for growth, which can lead to rapid price corrections if growth expectations are not met. |
| Competition risk (Diversified Life Science Providers) | Medium | Larger companies like Thermo Fisher and Danaher can leverage their scale to pressure pricing or bundle offerings. |
| Business quality | Strong | Repligen has high margins and a strong, recurring revenue model tied to essential bioprocessing consumables. |
| Dividend income | Low / none | Investors should not expect income, as all capital is directed toward growth and operations. |
| Execution risk | Medium | Successful growth depends on integrating acquisitions and maintaining technical relevance in a fast-evolving market. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 0.22% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.39B USD | Price to earnings Ratio - | 1Y Target Price 203.45 |
Price to earnings Ratio - | 1Y Target Price 203.45 | ||
Volume (30-day avg) 1.4M shares | Beta 1.12 | 52 Weeks Range 100.99 - 198.87 | Updated Date 11/05/2026 |
52 Weeks Range 100.99 - 198.87 | Updated Date 11/05/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.21 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Bioprocessing Consumables | Resins, filters, and fluid management components used in drug production. | The company earns the majority of its revenue from parts that biopharma companies must buy repeatedly. |
| Process Analytics & Equipment | Sensors and chromatography columns for monitoring and purification. | This segment provides the technology to ensure the quality of high-value medicine production. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-10-27 | When Before Market | Estimate 0.46 | Actual 0.53 |
Profitability
Profit Margin -1.47% | Operating Margin (TTM) 6.19% |
Management Effectiveness
Return on Assets (TTM) 1.4% | Return on Equity (TTM) -0.57% |
Valuation
Trailing PE - | Forward PE 62.11 | Enterprise Value 10.81B | Price to Sales(TTM) 14.14 |
Enterprise Value 10.81B | Price to Sales(TTM) 14.14 | ||
Enterprise Value to Revenue 13.42 | Enterprise Value to EBITDA 84.88 | Shares Outstanding 63.92M | Shares Floating 60.96M |
Shares Outstanding 63.92M | Shares Floating 60.96M | ||
Percent Insiders 4.63 | Percent Institutions 105.24 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.